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ARTICLE
Mortality outcomes with hydroxychloroquine and
chloroquine in COVID-19 from an international
collaborative meta-analysis of randomized trials
Substantial COVID-19 research investment has been allocated to randomized clinical trials
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or
early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine
on survival in COVID-19 from all currently available RCT evidence, published and unpub-
lished. We present a rapid meta-analysis of ongoing, completed, or discontinued RCTs on
hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: https://
osf.io/QESV4/). We systematically identified unpublished RCTs (ClinicalTrials.gov, WHO
International Clinical Trials Registry Platform, Cochrane COVID-registry up to June 11, 2020),
and published RCTs (PubMed, medRxiv and bioRxiv up to October 16, 2020). All-cause
mortality has been extracted (publications/preprints) or requested from investigators and
combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% con-
fidence intervals (CIs), separately for hydroxychloroquine and chloroquine. Prespecified
subgroup analyses include patient setting, diagnostic confirmation, control type, and pub-
lication status. Sixty-three trials were potentially eligible. We included 14 unpublished trials
(1308 patients) and 14 publications/preprints (9011 patients). Results for hydroxychloroquine
are dominated by RECOVERY and WHO SOLIDARITY, two highly pragmatic trials, which
employed relatively high doses and included 4716 and 1853 patients, respectively (67% of
the total sample size). The combined OR on all-cause mortality for hydroxychloroquine is 1.11
(95% CI: 1.02, 1.20; I²= 0%; 26 trials; 10,012 patients) and for chloroquine 1.77 (95%CI: 0.15,
21.13, I²= 0%; 4 trials; 307 patients). We identified no subgroup effects. We found that
treatment with hydroxychloroquine is associated with increased mortality in COVID-19
patients, and there is no benefit of chloroquine. Findings have unclear generalizability to
outpatients, children, pregnant women, and people with comorbidities.
https://doi.org/10.1038/s41467-021-22446-z OPEN
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Coronavirus disease 2019 (COVID-19) caused by severeacute respiratory syndrome coronavirus 2 (SARS-CoV-2)has the potential of progression into respiratory failure
and death1. More than 1,500,000 persons with COVID-19 glob-
ally have died by December 20202, and treatment options are
limited3. The COVID-19 pandemic has caused a hitherto
unprecedented search for possible therapies, with almost 700
clinical trials initiated in the first quarter of 2020—and one in five
of these trials target hydroxychloroquine (HCQ) or chloroquine
(CQ)4. This remarkable attention was primarily due to in vitro
data5, immunomodulatory capacities6, and the oral formulation
and well-documented safety profiles.
In March 2020, the US Food and Drug Administration (FDA)
issued an Emergency Use Authorization of HCQ7 and the
number of prescriptions and usage outside clinical studies
skyrocketed8. In many countries, HCQ or CQ were listed in
treatment guidelines for COVID-19 (including, e.g., China, Ire-
land, and the United States)9. In a New York City cohort of 1376
COVID-19 inpatients during March–April 2020, 59% received
HCQ10. However, the FDA revoked the Emergency Use
Authorization on June 15, 202011. At that point, two large ran-
domized clinical trials (RCTs), RECOVERY and the WHO Soli-
darity trial, had stopped enrollment to their HCQ treatment
arms12,13. An interim analysis of the RECOVERY trial showed no
mortality benefit of HCQ13. Established as treatments of malaria
and rheumatic disorders, HCQ and CQ may carry potentially
severe adverse effects, especially related to cardiac arrhythmia6.
Public uncertainty still remains, as illustrated by recent reports of
planned use in pandemic epicenters in Central and South
America14.
While many trials are ongoing, additional published evidence
of potential benefits or harms may be several months away, if they
even reach completion. Given the lack of favorable results in the
large RECOVERY trial and the revoked Emergency Use
Authorization, recruitment into HCQ and CQ trials has become
increasingly difficult and many trials may run the risk of ending
in futility. A rapid examination of data on all-cause mortality
from as many trials as possible may offer the best evidence on
potential survival benefits and to ensure that patients are not
exposed to unnecessary risks if benefit is lacking. We used the
infrastructure established with COVID-evidence15, a compre-
hensive database of COVID-19 trials funded by the Swiss
National Science Foundation, to invite all investigators of HCQ or
CQ trials to participate in an international collaborative meta-
analysis. We aimed to identify and combine all RCTs investi-
gating the effects of HCQ or CQ on all-cause mortality in patients
with COVID-19 compared to any control arm similar to the
experimental arm in all aspects except the administration of
HCQ or CQ.
In this work, we find that treatment with HCQ is associated with
increased mortality in COVID-19 patients, and there is no benefit
of CQ. Findings have unclear generalizability to outpatients, chil-
dren, pregnant women, and people with comorbidities.
Results
Our search identified 146 randomized trials investigating HCQ or
CQ as treatment for COVID-19, of which 83 were deemed
potentially eligible after scrutinizing the randomized compar-
isons. The investigators of these 83 trials were contacted and 57%
(47 of 83) responded (Fig. 1). Of the responders, 19 trials were
eligible and available (14 unpublished, one preprint, and four
publications); 21 trials were ineligible according to information
provided; five responding investigator teams were not ready to
share their results yet; and two declined participation. For the 36
trials without response, six were confirmed eligible and available
(four publications and two preprints); two were confirmed
ineligible; and for the remaining 28, results were not available, nor
could they be confirmed eligible.
We included 28 trials (14 unpublished trials, nine publications,
and five preprints; of these, one publication and two preprints
were identified for the first time in our search update)13,16–28.
Individual trial characteristics are presented in Table 1 (28
included trials) and Supplement Table S1 (34 potentially eligible
but unavailable). Overall, trial characteristics were not different
between included and unavailable trials (Table 2).
HCQ was evaluated in 26 trials (10,012 patients) and CQ was
evaluated in four trials (307 patients). Two trials investigated both
HCQ versus control and CQ versus control (63 patients). The
median sample size was 95 (interquartile range (IQR) 28–282) for
HCQ trials and 42 (IQR 29–95) for CQ trials. The two largest
trials (RECOVERY and WHO SOLIDARITY) included 47% and
19% of all patients in the HCQ trials, respectively. Most trials
investigated HCQ or CQ in hospitalized patients (22 trials; 79%),
and only five trials (18%) had an outpatient setting. The average
mortality was 10.3% (standard deviation 13.5%) in inpatient trials
and 0.08% (standard deviation 0.18%) in outpatient trials. The
comparator was in 11 trials placebo (39%) and in 17 (61%) no
other treatment than standard of care. In most trials, patients and
clinicians were aware of the treatment (15 trials; 54%), while in
one trial (4%) the patients were blinded and in 11 trials (39%)
patients and clinicians were blinded (Table 2). We identified no
relevant risk of bias across all trials, with only one trial including
seven patients having an overall high risk of bias (Table S2). We
found no evidence of small-study effects (Figure S1).
Regarding HCQ, in the 26 included trials, 606 of 4316 (14.0%)
patients treated with HCQ died and 960 of 5696 patients (16.9%)
in the control groups died (within 19 trials with a 1:1 randomi-
zation ratio, 7.7% of patients in the HCQ arm died [181 of 2346]
and 7.1% of patients in the control arm died [168 of 2352]). In the
meta-analysis, the combined odds ratio (OR) was 1.11 (95%
confidence interval (CI), 1.02–1.20, p= 0.02), with low hetero-
geneity (I2= 0%) (Fig. 2A). In 12 trials including a total of 1282
patients (representing 12.8% of the total sample size for HCQ),
there were zero deaths in both arms.
Regarding CQ, in the four included trials, 18 of 160 (11%)
patients treated with CQ died and 12 of 147 patients (8%) in the
control groups died. The combined OR was 1.77 (95% CI
0.15–21.13, p= 0.21), with low heterogeneity (I2= 0%) (Fig. 2B).
In two of four trials including a total of 217 patients, there were
zero deaths in both arms.
The available evidence in this study is the result of publications,
preprints, or unpublished trial results accrued from April 10,
2020 to October 16, 2020 as shown in the cumulative meta-
analyses (Fig. 3A–C).
For HCQ, none of the exploratory subgroup analyses showed an
effect modification (Supplement Table S3 and Figure S1A, B).
When only including published information (publications and
preprints, excluding unpublished trials), there was an increase in
mortality among patients treated with HCQ (OR 1.12, 95% CI
1.08–1.16), while among the unpublished trials there was no such
sign of increased mortality (OR 0.92, 95% CI 0.63–1.34, p for
interaction= 0.23). We conducted no subgroup analyses for CQ, as
there were only two trials with events. In the sensitivity analyses
employing different meta-analytical approaches (Supplement
Table S4 and Figures S2A–C), results were compatible with the
main analysis.
Discussion
This collaborative meta-analysis of 28 published or unpublished
RCTs, including 10,319 patients, shows that treatment with HCQ
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was associated with increased mortality in COVID-19 patients,
and there was no benefit from treatment with CQ. No differences
were seen across subgroup analyses on patient setting, diagnosis
confirmation, control type, publication status, or dose and the
between-study heterogeneity was low. For CQ, the number of
studies was too small to draw clear conclusions.
This meta-analysis offers useful insights for a challenging
health situation. Hundreds of thousands of patients have received
HCQ and CQ outside of clinical trials without evidence of their
beneficial effects. Public interest is unprecedented, with weak
early evidence supporting HCQ’s merits being widely discussed in
some media and social networks—despite the unfavorable results
by a very large RCT. Numerous clinical studies have been
investigating HCQ and CQ almost simultaneously. Although
several systematic reviews and meta-analyses are already avail-
able, they only consider the small handful of RCTs being already
published (which were all included here)29–33. While data sharing
has been rather limited to date in biomedical research, such
openness can be transformative in generating knowledge. This
pandemic has brought together a collaboration of clinical trialists
agreeing to share their data, which allows this study to not only
summarize the existing evidence but also illustrate the accumu-
lation of evidence that would otherwise not be available.
For HCQ, evidence is dominated by the RECOVERY trial13,
which indicated no mortality benefit for treated COVID-19
patients, together with longer hospitalization and higher risk of
progression to invasive mechanical ventilation and/or death.
Similarly, the WHO SOLIDARITY trial indicated no mortality
benefit26. The RECOVERY and WHO SOLIDARITY trials used
HCQ in comparatively higher doses than all other trials except
REMAP-CAP. There was no evidence for an effect modification
by dose (p for interaction= 0.29), and the combined effect of all
the trials with lower dose did not indicate a benefit of HCQ but
tended to a null effect (OR 0.97; 0.73–1.30) with wide CIs,
compatible with the main effect estimate.
This meta-analysis does not address prophylactic use nor other
outcomes besides mortality. All but three trials excluded children
and the majority excluded pregnant or breastfeeding women;
generalizability remains unclear for those populations. Among
the five studies on outpatients, there were three deaths, two
occurring in the one trial of 491 relatively young patients with few
comorbidities17 and one occurring in a small trial with 27
10097 excluded (non-trials, not 
COVID-19, duplicates)


















11 with unclear eligibility 
criteria
559 without HCQ or CQ
303 on HCQ or CQ





49 without a control arm that 
received neither HCQ nor CQ
14 with active control
36 no answer1 47 answered




10 not started / withdrawn
5 no data to contribute
1 not on HCQ or CQ
2 non-randomized
1 without eligible control
28 included trials
14 unpublished, 14 published2,3
on HCQ or CQ as treatment against 
COVID-19, randomized, with a 
placebo/standard of care control, started 
recruitment before June 1, 20203
35 excluded
28 unpublished & no answer
2 declined participation
5 answered, data unavailable 
before interim analysis
Fig. 1 Flowchart of included randomized clinical trials. Sources searched up to June 11, 2020 (PubMed, ClinicalTrials.gov, WHO ICTRP, Cochrane COVID
Register) or April 9 (WHO Literature database, bioRxiv, medRxiv, SwissEthics). 1Trials for which we received no answer were presumed to be eligible
unless withdrawn. 2One publication and two preprints were identified in a later search update. 3Published peer-reviewed articles or posted preprints. CQ
chloroquine, HCQ hydroxychloroquine, ICTRP International Clinical Trials Registry Platform, WHO World Health Organization.
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patients. For outpatients who are elderly or have comorbidities,
evidence is sparse. Most of the 28 trials excluded persons with
comorbid conditions carrying higher risk of adverse events from
HCQ or CQ16,17,27. No evidence is in the pipeline for these
groups, which echoes clinical reasoning being reluctant to expose
them to risk.
Although the published trials resulted in a conclusive treatment
estimate, the unpublished trials tend towards a null effect. The
tendency of published trials to report larger effect sizes than
unpublished trials is well-documented and constitute one of the
reporting biases that are discernable only when a body of studies
are considered together34. Null results are less expected to be
rapidly disseminated, especially if the trial is small. Of note,
RECOVERY results showing dexamethasone benefits have been
published more rapidly3 than the unfavorable HCQ results13. We
have found no evidence for small-study effects and we consider
that the results are unlikely to have been materially affected by
publication or reporting bias. This paper offers the most com-
prehensive summary on HCQ and mortality in COVID-19
to date.
Twenty-three percent of the potentially eligible trials were lis-
ted as discontinued, mostly because of fewer patients than
expected. Among 28 included RCTs, only two had reached their
target sample size at the time of censoring for this meta-analysis.
As previously discussed4, most trials on HCQ and CQ in COVID-
19 are small, reflecting both the strong motivation for individual
efforts and underscoring the need for readily available research
infrastructure to merge small-scale initiatives. Especially in the
context of recruitment challenges, we encourage other researchers
to form collaborations and combine trial results35.
Our analysis has some limitations. First, although we adopted a
comprehensive, systematic search strategy, our real-time initiative
differs from traditional systematic reviews. We focused on col-
lecting unpublished information, aiming to rapidly secure as much
trial evidence as possible. We did not review individual trials, nor
did we stratify results according to patient characteristics, and we
have not collected information on other outcomes than mortality.
Such analyses are planned in future publications using in-depth
details disclosed in individual trial publications to come36–38. The
exploratory subgroup analyses did not support the hypothesis that
blinding/use of placebo is associated with the observed effect (the
test for an interaction gives p= 0.15 and the OR is 0.88 with wide
CIs 0.55–1.41, compatible with the overall effect); moreover,
attrition was negligible (median 0%, IQR 0–0%; range 0–19.5%). A
meta-epidemiological study shows little evidence that mortality
results would be affected by lack of blinding, or problems in
randomization and allocation concealment, in contrast to less
objective outcomes39. Accordingly, we identified no relevant risk
of bias across trials. Second, a majority of the potentially eligible
trials were not available. Despite going far beyond the standard
review of published evidence, we expect additional results from
future trials on CQ to narrow the uncertainty of the treatment
effect and possibly reveal benefits or harms not discernible based
on the current evidence. We plan to perform an update when
substantial additional evidence becomes available. Third, although
this analysis intended to combine results from both inpatients and
outpatients regardless of disease severity, trials enrolling patients
with mild to moderate disease comprised a minority of the final
sample size; many of which had zero or few events. Finally,
although sensitivity analyses addressing model specifications were
compatible with the main analysis, one combination (HKSJ model
with SJ τ2 estimator) yielded substantially wider CIs. This com-
bination gave disproportionately low weight to RECOVERY (15%)
and we consider the main model (HKSJ with PM τ2 estimator) to
be more valid in this situation.
Treatment with HCQ for COVID-19 was associated with
increased mortality, and there was no benefit from CQ based on
currently available randomized trial data. Medical professionals
around the globe are encouraged to inform patients about this
evidence.
Methods
This collaborative meta-analysis focused solely on all-cause mortality in order to
provide rapid evidence on the most critical clinical outcome. Investigators of
ongoing, discontinued, or completed trials were contacted via email to provide
group-level (aggregated) mortality data per trial arm at any time point available.
The protocol was published online before data collection40. This review has been
reported in accordance with the Preferred Reporting Items for Systematic Review
and Meta-analysis41. The PRISMA checklist can be found in the supplement
(Supplement 1).









trialsa, n = 34
Drug, n (%)
HCQ 47 (76) 24 (86) 23 (68)
CQ 10 (16) 2 (7) 8 (22)
Both 5 (8) 2 (7) 3 (8)
Planned sample sizea
Median (IQR) 355 (150–630) 500 (218–1350) 254 (120–442)
Trial status, n (%)
Active, not
recruiting
1 (2) 0 (0) 1 (3)
Completed 13 (21) 12 (43) 1 (3)
Discontinued 6 (10) 0 (0) 6 (18)
Not yet
recruiting
2 (3) 0 (0) 2 (6)
Recruiting 27 (44) 8 (29) 19 (56)
Terminated 13 (21) 8 (29) 5 (15)
Location, n (%)
Africa 3 (5) 1 (4) 2 (6)
Asia 23 (37) 8 (29) 15 (44)
Europe 16 (26) 8 (29) 8 (24)
Internationalb 6 (10) 4 (14) 2 (6)
North America 10 (16) 4 (14) 6 (18)
South America 4 (6) 3 (11) 1 (3)
Placebo control,
n (%)
30 (47) 11 (39) 18 (53)
More than two
arms, n (%)
27 (44) 10 (37) 17 (50)
Patient setting, n (%)
ICU 1 (2) 1 (4) 0
Inpatient 45 (73) 22 (79) 23 (68)
Outpatient 12 (19) 5 (18) 7 (21)
Unclear 4 (6) 0 4 (12)
Blinding, n (%)
None 32 (52) 15 (54) 17 (50)
Outcome
assessor
1 (2) 1 (4) 0
Participant 3 (5) 1 (4) 2 (6)
Participant,
caregiver




1 (2) 0 1 (3)
CQ chloroquine, HCQ hydroxychloroquine, ICU intensive care unit, IQR interquartile range.
aData were extracted from trial registries or publications.
bIncluding centers in multiple countries.
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Eligibility criteria. We considered all clinical trials that reported randomly allocating
patients with confirmed or suspected SARS-CoV-2 infection to a treatment protocol
containing HCQ or CQ (for any duration or dose) or the same treatment protocol not
containing HCQ or CQ. In other words, the control group had to receive placebo or
no treatment other than standard of care (we excluded comparisons of HCQ or CQ
against an active treatment, e.g., HCQ versus azithromycin, since active controls were
too heterogeneous to pool together and reveal the pure benefits and harms of HCQ or
CQ). Eligible ongoing trials had to provide data on all-cause mortality and randomize
the first patient before June 1, 2020 (time point selected arbitrarily as we did not
expect trials launched later to recruit enough patients to provide relevant additional
information). Trials that were published or posted as preprint were not restricted by
date. Prevention trials were not included. We included trials regardless of follow-up
time and whether mortality was a primary outcome or not; moreover, we put no
restrictions on trial status, language, geographical region, or healthcare setting.
Random effects model
Heterogeneity: I 2 = 0%, τ2 = 0, p = 0.98
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Search strategy. We searched for eligible trials registered at ClinicalTrials.gov and
the WHO International Clinical Trials Registry Platform (ICTRP) by June 11, 2020
(COVID-evidence database; see Supplement 2)42. We additionally searched
PubMed and the Cochrane COVID-19 trial registry (covering preprints, trial
registries, and literature databases) by June 11, 2020, using terms related to HCQ
and CQ combined with terms for COVID-19 and a standard RCT filter
(Supplement 2)43. We updated the literature search on October 16, 2020. Two
authors (C.A. and A.M.S.) independently verified the eligibility criteria (Fig. 1) and
solved any discrepancies by discussion.
Principal investigators of 83 potentially eligible trials were asked to confirm the
eligibility criteria, as well as: “For each of your study arms: (a) What intervention
did this group receive? (b) How many patients were randomized to this group?
(c) Of these patients, how many have died? (d) Of these patients, for how many it is
unknown if they are dead or alive?” (Supplement 3, email template). Investigators
who were not responsive received two email reminders in English or Chinese,
depending on trial origin.
Data extraction. The following information was extracted from all included RCTs
by two reviewers (C.A. and A.M.S.) and verified by the trial investigators:
experimental and control arms, number of randomized participants, treatment
schedule, patient setting, eligibility criteria, study location, blinding, target sample
size, and trial status. We also classified trials as published in a peer-reviewed
journal, posted on a preprint server, or unpublished (the latter category not
including preprints). For reasons of feasibility within this rapid assessment, we
generally did not request descriptive information beyond items included in trial
registrations.
Risk of bias assessment. Two reviewers (C.A. and A.M.S.) independently assessed
the risk of bias of included RCTs using the Cochrane risk of bias tool 2.044.
Disagreements were resolved through discussion. We used the information
reported in preprints and journal publications, and for unpublished trials, we
retrieved information from trial registrations, which was confirmed by trial
investigators. We also assessed small-study effects with an inverted funnel plot and
Egger’s test43. The presence of small-study effects may be suggestive, but not
definitive, of publication bias45.
Data synthesis and analyses. The main analysis evaluated separately the effect on
all-cause mortality of HCQ versus control and CQ versus control. We report
absolute numbers and proportions, as well as the treatment effect estimate as an
odds ratio (OR; odds of death in the HCQ or CQ intervention group divided by the
odds of death in the control group) with 95% CIs. For multi-arm studies, we
requested data for all arms and calculated treatment effect estimates for each
eligible comparison. We combined mortality effects from all RCTs based on binary
outcome data (2 × 2 contingency tables) in meta-analyses and describe the statis-
tical heterogeneity using the I2 statistic46. In our protocol, we prespecified a
random-effects model of the Hartung–Knapp–Sidik–Jonkman (HKSJ) approach47,
in order to provide more equality of weights between trials with moderate to large
size (than, e.g., the DerSimonian–Laird approach). We did not prespecify the
between-study variance estimator, τ2, but chose the Paule and Mandel (PM)
estimator based on provided guidance on choosing among 16 variants48. Cases of
zero events in one arm were corrected by adding the reciprocal of the size of the
contrasting study arm43. However, considering the range of sample sizes and the
number of zero events across trials, we assessed the effects of alternative approa-
ches with sensitivity analyses, as detailed below. To explore and illustrate evidence
generation over time, we also performed a cumulative meta-analysis of all trials as
well as stratified by dissemination status (publications/preprints versus unpub-
lished), using the HKSJ approach with PM τ2. We used the date of email response
or publication/posting of preprint. The meta-analyses were completed using R
version 3.5.1 and the “meta” package version 4.13-0.
Subgroup analyses. In exploratory subgroup analyses, we stratified trials by
patient setting (as proxy to COVID-19 severity: outpatients, inpatients but not
intensive care unit (ICU), and ICU), diagnostic confirmation (confirmed SARS-
CoV-2 versus suspected cases), control type (placebo control versus other), and
publications/preprints versus unpublished trials. We did not stratify for missing
data since the amount was extremely low. A post hoc stratification by HCQ dose
was added (trials with ≥1600 mg on day 1 and ≥800 mg from day 2 versus lower-
dose trials) to isolate trials predicted to achieve blood levels of HCQ above the
in vitro half-maximal inhibitory concentration value for SARS-CoV-2 (1.13 μM)49.
Sensitivity analyses. We added exploratory sensitivity analyses to assess robust-
ness across meta-analytic approaches: DerSimonian–Laird and Sidik–Jonkman τ2
estimators, Mantel–Haenszel random-effects method, and Peto method.
DerSimonian–Laird is a standard random-effects meta-analysis approach, but may
underestimate uncertainty. The Sidik–Jonkman τ2 estimator, on the other hand,
may yield inflated estimates if heterogeneity is low48. The Mantel–Haenszel
method performs reasonably well with small and zero event counts, much like Peto
and arcsine transformation. The Peto method is suboptimal in the presence of
substantial imbalances in the allocation ratio of patients randomized in the com-
pared arms (e.g., RECOVERY trial). We also modeled variants to handling zero
events (arcsine difference, and excluding trials with zero events) as well as
excluding trials with <50 participants.
Unpublished trial details. All unpublished trials were performed according to the
principles of the Declaration of Helsinki and written informed consent was
obtained from the study participants. The release of mortality outcome data was
authorized by the respective data and safety monitoring boards and principal
investigators. Ethical approval was granted by institutional review boards as fol-
lows: University of Pennsylvania, ref. #842838 (PATCH, NCT04329923); National
Bioethics Committee (NBC) Pakistan, ref. 4–87/NBC-471-COVID-19-05/20/
(PROTECT, NCT04338698); Ethics Committee of the Capital Region of Denmark,
ref. H-20025317 (CCAP-1, NCT04345289); Comité de Protection des Personnes
du Sud-Ouest et Outre-Mer 4, ref. CPP2020-03-036/2020-001271-33/
20.03.24.72431, and the Agence Nationale de Sécurité du Médicament et des
produits de santé (ANSM), ref. MEDAECNAT-2020-03-00045 (HYCOVID,
NCT04325893); Ethik-Kommission an der Medizinischen Fakultät der Eberhard-
Karls-Universität und am Universitätsklinikum Tübingen, ref. 190/2020AMG1 and
ref. 225/2020AMG1 (COV-HCQ, NCT04342221; and COMIHY, NCT04340544,
respectively); London-Surrey Borders Research Ethics Committee in the UK,
Medisch Ethische Toetsingscommissie Utrecht (METC Utrecht) in the Nether-
lands, Sydney Local District ethics Review Committee (Royal Prince Alfred Hos-
pital) in Australia, Northern A Health and Disability Ethics Committee in New
Zealand, St. Vincent’s Healthcare Group Ethics and Medical Research Committee
in Ireland, King Abdullah International Medical Research Center Institutional
Review Board in Saudi Arabia, University of Pittsburgh Institutional Review Board
in the United States, Unity Health Research Ethics Board in Canada, National
Ethics Committee for Clinical Research (CEIC) in Portugal, and the Romania
Academy of Medical Sciences National Bioethics Committee for Medicines and
Medical Devices (REMAP-CAP, NCT02735707); Comissão Nacional de Ética em
Pesquisa (CONEP), ref. 3.961.681 (CloroCOVID19II A, NCT04323527, and
CloroCOVID19II B, NCT04342650); a Single Ethics Committee from the Coor-
dination of the National Institutes of Health and High Specialty Hospitals, ref. C13-
20 (HYDRA, NCT04315896); the Ethics Committee of Beijing Youan Hospital,
Capital Medical University, ref. JINYOUKELUN[2020]013 (ChiCTR2000031204);
Partners Human Research Committee at the Brigham and Women’s Hospital,
Boston, Ethisch Comite in Belgium, and Stichting Beoordeling Ethiek Biomedisch
in the Netherlands (NCT04333654); The Queen’s Medical Center, ref. RA-2020-
018 (OAHU-COVID19, NCT04345692); Duke University Medical Center Insti-
tutional Review Board, ref. Pro00105339, and UnityPoint Health Institutional
Review Board (NCT04335552); and Medical Ethics Committee Utrecht (METC
Utrecht), part of the Dutch Central Committee on Research Involving Human
Subjects (ARCHAIC, NL8490).
Fig. 2 Random effects meta-analysis for mortality for treatment of COVID-19, trials are stratified by publication status. A Random-effects meta-
analysis for mortality for treatment of COVID-19 with Hydroxychloroquine, trials are stratified by publication status. The dashed vertical line denotes an
odds ratio of 1.0, which represents no difference in risk between hydroxychloroquine and the control. The black horizontal bars represent 95% confidence
intervals (CIs). Random-effects model of the Hartung–Knapp–Sidik–Jonkman approach was performed to obtain a pooled estimate of the odds ratio. The
estimate of heterogeneity (τ2) was obtained using the Paule and Mandel (PM) estimator. We describe the between-trial heterogeneity using the I2
statistic. The results of the statistical tests for the overall effect and corresponding p values are presented. All tests were two-tailed. *Published as peer-
reviewed articles or posted preprints. B Random-effects meta-analysis for mortality for treatment of COVID-19 with chloroquine. The dashed vertical line
denotes an odds ratio of 1.0, which represents no difference in risk between chloroquine and the control. The black horizontal bars represent 95%
confidence intervals (CIs). Random-effects model of the Hartung–Knapp–Sidik–Jonkman approach was performed to obtain a pooled estimate of the odds
ratio. The estimate of heterogeneity (τ2) was obtained using the Paule and Mandel (PM) estimator. We describe the between-trial heterogeneity using the
I2 statistic. The results of the statistical tests for the overall effect and corresponding p values are presented. All tests were two-tailed. The x-axis scales
differ for reasons of readability. Source data are provided as a Source Data file.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All trial-level data generated or analyzed during this study are included in this published
article and its Supplementary information files. The data file is provided in the Open
Science Framework [https://osf.io/qesv4/]40. Source data are provided with this paper.
Code availability
The code file is provided in the Open Science Framework [https://osf.io/qesv4/]40.
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Fig. 3 Cumulative meta-analysis for mortality for treatment of COVID-19
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represents no difference in risk between hydroxychloroquine and the
control. The black horizontal bars represent 95% confidence intervals (CIs).
Random-effects model of the Hartung–Knapp–Sidik–Jonkman approach was
performed to obtain a pooled estimate of the odds ratio. The estimate of
heterogeneity (τ2) was obtained using the Paule and Mandel (PM)
estimator. We describe the between-trial heterogeneity using the I2 statistic.
The results of the statistical tests for the overall effect and corresponding p
values are presented. All tests were two-tailed. B Cumulative meta-analysis
for mortality for treatment of COVID-19 with hydroxychloroquine
(publications and preprints only). HCQ was evaluated in 14 published trials
with 8981 patients. Three thousand eight hundred and nine patients were
treated with hydroxychloroquine, of whom 547 died. Five thousand one
hundred and seventy-two patients were allocated to the control group, of
whom 893 died.The dashed vertical line denotes an odds ratio of 1.0, which
represents no difference in risk between hydroxychloroquine and the
control. The black horizontal bars represent 95% confidence intervals (CI).
Random-effects model of the Hartung–Knapp–Sidik–Jonkman approach was
performed to obtain a pooled estimate of the odds ratio. The estimate of
heterogeneity (τ2) was obtained using the Paule and Mandel (PM)
estimator. We describe the between-trial heterogeneity using the I2 statistic.
The results of the statistical tests for the overall effect and corresponding p
values are presented. All tests were two-tailed. C Cumulative meta-analysis
for mortality for treatment of COVID-19 with hydroxychloroquine
(unpublished data only). HCQ was evaluated in 12 unpublished trials with
1031 patients. Five hundred and seven patients were treated with
hydroxychloroquine, of whom 59 died. Five hundred and twenty-four
patients were allocated to the control group, of whom 67 died. The dashed
vertical line denotes an odds ratio of 1.0, which represents no difference in
risk between hydroxychloroquine and the control. The black horizontal bars
represent 95% confidence intervals (CIs). Random-effects model of the
Hartung–Knapp–Sidik–Jonkman approach was performed to obtain a pooled
estimate of the odds ratio. The estimate of heterogeneity (τ2) was obtained
using the Paule and Mandel (PM) estimator. We describe the between-trial
heterogeneity using the I2 statistic. The results of the statistical tests for the
overall effect and corresponding p values are presented. All tests were two-
tailed. The x-axis scales differ for reasons of readability. Source data are
provided as a Source Data file.
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